These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21936971)

  • 21. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity analysis for handling uncertainty in an economic evaluation.
    Limwattananon S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S59-64. PubMed ID: 24964700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring structural uncertainty in model-based economic evaluations.
    Afzali HH; Karnon J
    Pharmacoeconomics; 2015 May; 33(5):435-43. PubMed ID: 25601288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic data transferability for HTA: are we there yet?
    Manca A
    Value Health; 2009 Jun; 12(4):407. PubMed ID: 19900247
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of cost-effectiveness analysis in health care decision-making.
    Magel JS
    Physician Exec; 1990; 16(3):31-2. PubMed ID: 10113233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
    Forster M; Pertile P
    Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wise buys.
    Freemantle N
    Health Serv J; 1992 Jan; 102(5285):23. PubMed ID: 10116994
    [No Abstract]   [Full Text] [Related]  

  • 30. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is high-tech treatment worth the cost?
    Kastiel DL
    Bus Insur; 1985 Nov; 19(44):30. PubMed ID: 10274034
    [No Abstract]   [Full Text] [Related]  

  • 32. Health technology assessment in Europe.
    Kristensen FB
    Scand J Public Health; 2009 Jun; 37(4):335-9. PubMed ID: 19493989
    [No Abstract]   [Full Text] [Related]  

  • 33. Technology assessment and the doctor-patient relationship.
    Wax AL
    Va Law Rev; 1996 Nov; 82(8):1641-62. PubMed ID: 16715567
    [No Abstract]   [Full Text] [Related]  

  • 34. Health technology assessment and clinical decision making: which is the best evidence?
    Granados A
    Int J Technol Assess Health Care; 1999; 15(3):585-92. PubMed ID: 10874384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost/benefit analysis-another dimension.
    Hess OW
    Med Instrum; 1982; 16(1):76-7. PubMed ID: 6801445
    [No Abstract]   [Full Text] [Related]  

  • 36. EXPANDING EVIDENCE-BASED TECHNOLOGY ASSESSMENT FOR COVERAGE IN WASHINGTON STATE.
    Landaas EJ; Franklin G; Thompson J; Lessler D; Morse J; Mootz R; Hammond SG; Sullivan SD
    Int J Technol Assess Health Care; 2016 Jan; 32(3):140-6. PubMed ID: 27491675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health technology assessment in the cost-disutility plane.
    Eckermann S; Briggs A; Willan AR
    Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines.
    Ghabri S; Cleemput I; Josselin JM
    Pharmacoeconomics; 2018 Feb; 36(2):127-130. PubMed ID: 29264865
    [No Abstract]   [Full Text] [Related]  

  • 39. Ten arguments for a societal perspective in the economic evaluation of medical innovations.
    Jönsson B
    Eur J Health Econ; 2009 Oct; 10(4):357-9. PubMed ID: 19618224
    [No Abstract]   [Full Text] [Related]  

  • 40. Introducing the JME special issue on cost-effectiveness analyses.
    Lee K
    J Med Econ; 2012; 15 Suppl 1():1-2. PubMed ID: 23163333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.